PKM and cancer: Taken together, this meta analysis demonstrates that over-expression of PKM2 in solid tumor tissues, as measured by immunohistochemistry, is associated with a poor prognosis in most solid tumors, which suggests that PKM2 might be a potential prognostic biomarker and targeting PKM2 could be a promising therapeutic approach for treating solid tumors in a variety of cancer types.